Journal
FRONTIERS IN GENETICS
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2020.614726
Keywords
alpha-enolase; autoantibodies; cancer biomarker; therapeutic target; ENO1
Categories
Funding
- National Institutes of Health (NIH) [P20MD006988, R21CA226654-01A1]
- Loma Linda University (LLU) Center for Health Disparities and Molecular Medicine
- LLU School of Medicine
- LLU Cancer Center
- NIH [R25GM060507]
- LLU-NIH Initiative for Maximizing Student Development (IMSD) graduate training program
Ask authors/readers for more resources
ENO1 is a glycolytic enzyme that also acts as a plasminogen receptor on the cell surface, contributing to cancer cell proliferation and metastasis. Its overexpression in various cancers is associated with poor prognosis and the generation of anti-ENO1 autoantibodies, making it a potential therapeutic target and cancer biomarker.
Alpha-enolase, also known as enolase-1 (ENO1), is a glycolytic enzyme that moonlights as a plasminogen receptor in the cell surface, particularly in tumors, contributing to cancer cell proliferation, migration, invasion, and metastasis. ENO1 also promotes other oncogenic events, including protein-protein interactions that regulate glycolysis, activation of signaling pathways, and resistance to chemotherapy. ENO1 overexpression has been established in a broad range of human cancers and is often associated with poor prognosis. This increased expression is usually accompanied by the generation of anti-ENO1 autoantibodies in some cancer patients, making this protein a tumor associated antigen. These autoantibodies are common in patients with cancer associated retinopathy, where they exert pathogenic effects, and may be triggered by immunodominant peptides within the ENO1 sequence or by posttranslational modifications. ENO1 overexpression in multiple cancer types, localization in the tumor cell surface, and demonstrated targetability make this protein a promising cancer biomarker and therapeutic target. This mini-review summarizes our current knowledge of ENO1 functions in cancer and its growing potential as a cancer biomarker and guide for the development of novel anti-tumor treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available